Evidence map›Paper›PMID 27379343›Full record

ArticleACS infectious diseases2016

Identification of small molecule inhibitors that block the

Catherine Simpson, Nathaniel G Jones, Emily A Hull-Ryde, Dmitri Kireev, Michael Stashko, Keliang Tang, Jim Janetka, Scott A Wildman, William J Zuercher, Matthieu Schapira and 3 more

Open access · greenAbstract read
In one paragraph

Article in ACS infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Identification of Small-Molecule Inhibitors ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Therapeutic Antitoxoplasmosis Potential ofJournal of tropical medicine · 2026
    Article
  3. Article
  4. Released Parasite-Derived Kinases as Novel Targets for Antiparasitic Therapies.Frontiers in cellular and infection microbiology · 2022
    Review
  5. Review
  6. Dual-Stage Picolinic Acid-Derived Inhibitors ofACS medicinal chemistry letters · 2020
    Article
  7. Article
  8. Article
  9. Article
  10. The Expressed MicroRNA-mRNA Interactions ofFrontiers in microbiology · 2017
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Catherine SimpsonCenter for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina, 125 Mason Farm Road, CB#7363, Chapel Hill, NC 27599-7363.
Nathaniel G JonesDepartment of Molecular Microbiology, Washington University Sch. Med. St. Louis MO 63110.
Emily A Hull-RydeCenter for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina, 125 Mason Farm Road, CB#7363, Chapel Hill, NC 27599-7363.
Dmitri KireevCenter for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina, 125 Mason Farm Road, CB#7363, Chapel Hill, NC 27599-7363.
Michael StashkoCenter for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina, 125 Mason Farm Road, CB#7363, Chapel Hill, NC 27599-7363.
Keliang TangDepartment of Molecular Microbiology, Washington University Sch. Med. St. Louis MO 63110.
Jim JanetkaDepartment of Biochemistry and Molecular Biophysics, Washington University Sch. Med. St. Louis MO 63110.
Scott A WildmanDepartment of Biochemistry and Molecular Biophysics, Washington University Sch. Med. St. Louis MO 63110.
William J ZuercherSGC-UNC, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, 120 Mason Farm Rd, 1070H Genetic Medicine Building, University of North Carolina, NC 27599-7363.
Matthieu SchapiraStructural Genomics Consortium, University of Toronto, MaRS South Tower, 101 College St, Toronto, ON, M5G 1L7, Canada; Department of Pharmacology and Toxicology, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.
Raymond HuiStructural Genomics Consortium, University of Toronto, MaRS South Tower, 101 College St, Toronto, ON, M5G 1L7, Canada; Toronto General Hospital Research Institute, 200 Elizabeth St., Toronto, ON M5G 2C4, Canada.
William JanzenCenter for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina, 125 Mason Farm Road, CB#7363, Chapel Hill, NC 27599-7363.
L David SibleyDepartment of Molecular Microbiology, Washington University Sch. Med. St. Louis MO 63110.
University of North Carolina at Chapel Hill · USCanada Research Chairs · CAStructural Genomics Consortium · CA

Funding

Molecular Basis of Human ToxoplasmosisR01AI118426 · NIAID · WASHINGTON UNIVERSITY · PI SIBLEY, L. DAVID · 2015 to 2024
$6.0M
TARGETING ESSENTIAL ROP KINASES IN TOXOPLASMAR01AI082423 · NIAID · WASHINGTON UNIVERSITY · PI SIBLEY, L. DAVID · 2009 to 2015
$2.9M
NIAID NIH HHS R01 AI082423NIAID NIH HHS R01 AI118426Wellcome Trust
6 · The paper itself

Abstract

The protozoan parasite

Indexed as

high throughput screeninginterferonpathogenphosphorylationtoxoplasmosisvirulence

Identifiers

PMID27379343
PMCPMC4930114
OpenAlexW2235875490

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.